SG Americas Securities LLC Grows Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

SG Americas Securities LLC raised its stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 401.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 98,253 shares of the company’s stock after buying an additional 78,656 shares during the period. SG Americas Securities LLC owned about 0.15% of Trevi Therapeutics worth $132,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SNC purchased a new stake in Trevi Therapeutics in the 2nd quarter valued at about $26,000. Virtu Financial LLC purchased a new stake in shares of Trevi Therapeutics in the 4th quarter worth approximately $27,000. Citigroup Inc. purchased a new stake in shares of Trevi Therapeutics in the 2nd quarter worth approximately $30,000. California State Teachers Retirement System purchased a new stake in shares of Trevi Therapeutics in the 2nd quarter worth approximately $33,000. Finally, Barclays PLC purchased a new stake in shares of Trevi Therapeutics in the 2nd quarter worth approximately $34,000. 95.76% of the stock is owned by hedge funds and other institutional investors.

Trevi Therapeutics Stock Down 3.2 %

NASDAQ TRVI opened at $2.58 on Thursday. The firm has a market cap of $177.92 million, a PE ratio of -8.90 and a beta of 0.86. The company has a 50 day moving average price of $2.89 and a 200 day moving average price of $1.97. Trevi Therapeutics, Inc. has a 52 week low of $0.97 and a 52 week high of $4.00.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings data on Wednesday, March 20th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.02. On average, equities research analysts anticipate that Trevi Therapeutics, Inc. will post -0.39 earnings per share for the current fiscal year.

Analyst Ratings Changes

TRVI has been the subject of several research reports. Oppenheimer reaffirmed an “outperform” rating and issued a $9.00 price target on shares of Trevi Therapeutics in a research report on Thursday, March 21st. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price target on shares of Trevi Therapeutics in a research report on Tuesday, April 9th.

Trevi Therapeutics Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.